Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03253250 Recruiting - Chronic Hepatitis b Clinical Trials

The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection

Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

The current study is a prospective, randomized, open, multi-center investigation. The aim of current study is to investigate whether the Recurrence-free Survival Rate (RFS)of the hepatitis B related -hepatocellular carcinoma subjects who have been treated by resection can be improved by peginterferon alfa-2a

NCT ID: NCT03248375 Completed - Clinical trials for Hepatocellular Carcinoma

Impact of Y90 Radiation Segmentectomy on HCC

Start date: August 3, 2016
Phase: N/A
Study type: Interventional

The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are unable to receive thermal ablation due to unfavorable location of target lesions.

NCT ID: NCT03247296 Active, not recruiting - Hepatitis C Clinical Trials

Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir

Start date: February 28, 2017
Phase: N/A
Study type: Observational

To evaluate the early detection of HCC in patients Taking Sofosbuvir and Daclatasvir.

NCT ID: NCT03245190 Completed - Clinical trials for Hepatocellular Carcinoma

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Start date: April 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

NCT ID: NCT03243916 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC

Start date: August 15, 2017
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma is a highly malignant tumor that is progressing rapidly. Hepatic arterial embolization chemotherapy (TACE) is a common method for the treatment of unresectable of hepatocellular carcinoma.But for patients with > 10cm hepatocellular carcinoma, the intervention effect was not satisfied.The cyberknife is a kind of stereotactic radiotherapy which can track the movement of tumor and monitor the position deviation of tumor in real time.This stuy is aimed to observe the efficiency and safety of the combination of TACE and cyberknife in the treatment of massive hepatocellular carcinoma.

NCT ID: NCT03236649 Terminated - Clinical trials for Hepatocellular Carcinoma (HCC)

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Start date: September 20, 2017
Phase: Phase 3
Study type: Interventional

The primary efficacy index of this study is to compare the OS of the two groups.

NCT ID: NCT03236636 Recruiting - Clinical trials for Advanced HBV-Related Hepatocellular Carcinoma (HCC)

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Start date: September 8, 2017
Phase: Phase 3
Study type: Interventional

The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.

NCT ID: NCT03235167 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Start date: October 2017
Phase: Phase 1
Study type: Interventional

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

NCT ID: NCT03233360 Completed - Clinical trials for Hepatocellular Carcinoma

Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry

INSIGHT
Start date: April 17, 2017
Phase:
Study type: Observational

The INSIGHT ('Insight into Real-world Practice of Management of HCC in Asia-Pacific') registry is designed as a multi-centre longitudinal cohort study of patients diagnosed with HCC between 1st January 2013 and 31st December 2019 in nine countries (i.e., South Korea, Taiwan, Thailand, Japan, China, Hong Kong, Australia, New Zealand and Singapore). Approximately 30% of the sample size will be identified retrospectively and 70% will be identified prospectively from the start date of the registry (October 2016), with an even distribution of consecutively diagnosed patients within the different years.

NCT ID: NCT03230318 Completed - Clinical trials for Intrahepatic Cholangiocarcinoma

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

FIDES-01
Start date: September 28, 2017
Phase: Phase 2
Study type: Interventional

This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazantinib capsules.